High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients

@inproceedings{Delord2013HighID,
  title={High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients},
  author={Marc Delord and Philippe Rousselot and Jean Michel Cayuela and François Sigaux and Jo{\"e}lle Guilhot and Claude Joseph Preudhomme and François Guilhot and Pascale Loiseau and Emmanuel Raffoux and Daniela Geromin and Emmanuelle G{\'e}nin and Fabien Calvo and Heriberto Bruzzoni-Giovanelli},
  booktitle={Oncotarget},
  year={2013}
}
Pharmacogenetic studies in chronic myelogenous leukemia (CML) typically use a candidate gene approach. In an alternative strategy, we analyzed the impact of single nucleotide polymorphisms (SNPs) in drug transporter genes on the molecular response to imatinib, using a DNA chip containing 857 SNPs covering 94 drug transporter genes. Two cohorts of CML patients treated with imatinib were evaluated: an exploratory cohort including 105 patients treated at 400 mg/d and a validation cohort including… CONTINUE READING
7 Citations
48 References
Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 48 references

Genetic polymorphisms of metabolic enzymes CYP1A1, CYP2D6, GSTM1 and GSTT1 and leukemia susceptibility

  • Chen H-C, Hu W-X, Liu Q-X, Li W-K, Chen F-Z, Rao
  • Oncotarget
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…